Accumetrics News
Accumetrics Announces The Launch and First Patient Enrolled into the GRAVITAS TrialSan Diego, CA, June 16, 2008 - Patient enrollment into the GRAVITAS (Gauging Responsiveness With A VerifyNow® Assay-Impact On Thrombosis And Safety) trial has begun, officials from Accumetrics announced today. The GRAVITAS trial is designed to evaluate the use of the VerifyNow P2Y12 test to identify patients that exhibit a low response to antiplatelet therapy who are at risk for adverse cardiac events, and prove that these at-risk patients will benefit from tailored antiplatelet therapy. Read More |
Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical TrialAccumetrics, Inc. a privately-held medical device company and maker of the VerifyNow family of tests that measure patient response to antiplatelet drugs, announced today that it has raised $28.8 million in its Series D financing. The syndicate was led by Arnerich Massena & Associates, Inc. and BBT Fund, L.P. Also participating in the round were previous investors: Essex Woodland Health Ventures, RiverVest, PTV Sciences, KB Partners and Kaiser Permanente Ventures. Read More |
